Metformin glycinate - Laboratorios Silanes

Drug Profile

Metformin glycinate - Laboratorios Silanes

Alternative Names: DDMET-01; Metformin glycinate

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Laboratorios Silanes
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 12 Apr 2016 Metformin glycinate is still in phase III trials for Type-2 diabetes mellitus (Treatment-naive) in Mexico (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Feb 2014 Laboratorios Silanes completes enrolment in the phase III COMET trial for Type-2 diabetes mellitus (treatment-naive) in Mexico (NCT01386671)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top